linjc16/ctgov huggingface dataset:
Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination

Study Overview
=================
Brief Summary
-----------------
To evaluate the performance of an interactive chatbot and assess its effectiveness for enhancing informed decisions made by cataract patients.

Official Title
-----------------
Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Device: Chatbot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals aged over 18 years who have been resident in the selected study district for more than six months; Willing to participate the study and provide informed consent. Exclusion Criteria: Having ocular, hearing or mental disorders precluding reading or telephone interview.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Interactive Q&A chatbot<br>A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination. | Device: Chatbot<br>* An interactive chatbot for patient decision aid A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of COVID-19 vaccination.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Informed choice about COVID-19 vaccination (the proportion of participants who make an informed choice，which is defined as a good knowledge score and an intention that is consistent with their attitude score) | Informed choice is an aggregated measure of multiple measurements, including knowledge (a 10-item questionnaire that assesses knowledge), attitudes (6 items, with 5 responses for each), and intentions (single item with 5 responses) | 2 weeks post intervention |
Evolution of the State of Health of Patients Undergoing Surgery for Osteoarticular Surgery

Study Overview
=================
Brief Summary
-----------------
Osteoarticular surgery is frequently associated with the occurrence of moderate to severe postoperative pain. This pain can persist and become chronic post-surgical pain that is often debilitating. The transition between early postoperative pain and chronic pain is poorly understood, which complicates treatment.

Official Title
-----------------
Evolution of the State of Health of Patients Undergoing Surgery for Osteoarticular Surgery: Retrospective Study Based on the Point of View of Patients

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patient aged ≥18 years Underwent osteoarticular surgery between 01/01/2019 and 31/12/2022. Having been followed up with the administration of at least 1 QoR-15F questionnaire postoperatively Subject who has not expressed his opposition to the reuse of his data for scientific research purposes. Exclusion criteria: - Subject who expressed their opposition to participating in the study has

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score measurement of the QoR-15F questionnaire | This conditional probability will be based on the score measurement of the QoR-15F questionnaire | Score measured on D1, D3, D14 and D28 postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoarthritis, Chronic pain, Osteoarticular surgery
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

Study Overview
=================
Brief Summary
-----------------
The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia). At least 600 subjects with a similar medical condition will take part in this study.

Detailed Description
-----------------
Objectives: To evaluate the safety and efficacy of the combination product niacin ER and simvastatin (NS) in patients with primary type II dyslipidemia and to descriptively compare flushing rates between two Titration Schedules for NS.

Official Title
-----------------
An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: Niacin Extended-Release and simvastatin Tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has primary Type II hyperlipidemia or mixed dyslipidemia. If the patient is currently taking a lipid modifying medication other than Zocor & he/she is willing to discontinue this medication LDL-C levels and/or non HDL-C levels above normal. Reasonable compliance with a standard cholesterol-lowering diet for a minimum of 4 weeks prior to screening and for the duration of the study. Exclusion Criteria: Patient has an allergy, hypersensitivity, or intolerance to niacin, statins, or their derivatives. HbA1c ≥ 9% in diabetic patients

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Niacin Extended-Release and simvastatin Tablets|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Niacin, Statin, Zocor, Simvastatin, Coronary Heart Disease, Dyslipidemia, Atherosclerosis, Hypercholesterolemia, Stroke, High-Density Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, Lipoprotein, Lipid, Niacin ER/simvastatin, Total Cholesterol, Triglycerides
Uremic Toxins in the Intensive Care Units (ICU): Patients With Lactate Acidosis

Study Overview
=================
Brief Summary
-----------------
Study of the kinetics of uremic toxins in the ICU patients with acute renal failure, in order to optimize the dialysis dose: patients with lactate acidosis. The sampling of blood and dialysate will be done during dialysis with different durations (4, 6 and 8 h)

Official Title
-----------------
Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Lactate Acidosis

Conditions
-----------------
Acute Renal Failure

Intervention / Treatment
-----------------
* Procedure: Dialysis during 4 hours
* Procedure: Dialysis during 6 hours
* Procedure: Dialysis during 8 hours


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Includes ICU patients with lactate acidosis with acute renal failure Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Dialysis during 4 hours | Procedure: Dialysis during 4 hours<br>* Blood and dialysate sampling<br>|
| Experimental: 2<br>Dialysis during 6 hours | Procedure: Dialysis during 6 hours<br>* Blood and dialysate sampling<br>|
| Experimental: 3<br>Dialysis during 8 hours | Procedure: Dialysis during 8 hours<br>* Blood and dialysate sampling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxin removal |  | During dialysis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients, ICU, lactate, acidosis
Evaluation of Meibomian Gland Dysfunction in Chinese Old Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify age-related changes in chinese meibomian glands that may be associated with meibomian gland dysfunction (MGD).

Conditions
-----------------
Dry Eye

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have dry eye symptom have meibomian gland dysfunction Exclusion Criteria: diabetes history of ocular surgery systemic disease or inflammation

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group1<br>This study was consisted of patients with older than 40 years of age who complained with dry eye. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tear film break-up time | Tear film break-up time (TBUT) was evaluated by placing a single fluorescein strip over the inferior tear meniscus after instilling a drop of normal saline. | 1 year | 
| Lower tear meniscus | Lower tear meniscus was evaluated by keratography | 1 year | 
| The morphology of meibomian glands | The morphology of meibomian glands was evaluated by keratography | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aged, Meibomian Glands, dry eye, Elderly
Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF

Study Overview
=================
Brief Summary
-----------------
To evaluate the influence of circadian rhythm on progesterone levels during follicular phase of natural cycle and during follicular phase of controlled ovarian stimulation during IVF.

Detailed Description
-----------------
The primary aim of this study is to determine the circadian rhythm of progesterone in a stimulated cycle. Sample size calculations show that the study needs to recruit 10 women to show any significant differences in progesterone secreted in the morning at 8 am compared to that secreted in the evening at 8 pm. We have increased the number of participants to 12 in order to compensate for any possible drop outs. The hormones FSH, LH, Progesterone and Estradiol will be measured at days 2/3, 8, 10 and 12 of a normal and stimulated cycle so that each patient serves as her own control. This study will provide the basis to establish the optimal blood sampling time for progesterone measurement and to more accurately determine the cut-off level for progesterone for favourable pregnancy outcomes in ART.

Official Title
-----------------
Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF

Conditions
-----------------
Ovarian Hyperstimulation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for IVF / ICSI - treatment Age ≥ 18 years and ≤ 35 years Ovarian reserve parameters in the adequate age - range, determined by Anti-Mullerian-Hormone (AMH) and Antral Follicle Count (AFC)(16) Able to understand the aim of the study and to provide consent Regular cycle (25-35 days) Exclusion Criteria: Diagnosis of polycystic ovarian syndrome (PCOS) Rotterdam criteria Endometriosis stage 3 or 4 AFS Treatment with GnRH-analogues during the previous 6 months Intake of oral contraceptive pill (OCP) or any hormonal treatment during the last 3 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progesterone levels during follicular phase | The primary aim of this study is to determine the circadian rhythm of progesterone in a stimulated cycle. | 2-4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
P4,ART,IVF,FSH,LH,AMH
Effect of Weight Reduction on Inflammatory Markers and Genes Expression in Obese Individuals

Study Overview
=================
Brief Summary
-----------------
To investigate whether weight reduction by life style modification for 12 weeks will improve circulating inflammatory markers, adipocytokines as well as gene expression of proinflammatory protein obtained from circulating monocytes from obese individuals.

Conditions
-----------------
Obesity, Inflammation

Intervention / Treatment
-----------------
* Behavioral: Lifestyle modification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nondiabetes obese individuals with BMI greater than 27 kgs/m2 Exclusion Criteria: Diabetes Abnormal hepatic, renal and cardiac function

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Lifestyle modification|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory responses after weight reduction |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BMI |  |  | 
| Circulating inflammatory markers |  |  | 
| Adipocytokines |  |  | 
| Gene Expression from mononuclear cells |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Inflammation
To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This is an open-label, multiple-dose study to evaluate the plasma and CSF pharmacokinetics of K0706 in healthy adult male subjects.

Official Title
-----------------
A Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: K0706
* Drug: K0706
* Drug: K0706


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult male subjects, 18 to 45 years of age, inclusive, at screening. Willing and able to give written, and dated an informed consent. Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions in the Investigator's opinion, and be accessible for follow-up. Medically healthy on the basis of medical history and physical examination. Subjects enrolled in the study should not father a child and follow the necessary precautionary measure to be taken during the course of the study. Exclusion Criteria: Subjects with a history of a frequent headache, nausea, or vomiting suggestive of increased intracranial pressure. Subject report of recent (6-month) alcohol abuse or illicit drug use or who tests positive at screening, Check-in, or outpatient Visits for breath alcohol and/or drugs of abuse or cotinine; Subjects with a history of any relevant allergy/hypersensitivity. Subjects determined by the investigator to have any medical condition that could jeopardize their health or prejudice the results. Subjects who have participated in CSF collection studies within 56 days prior to check-in. Subjects who donated plasma within 14 days prior to the check-in visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br> | Drug: K0706<br>* Study<br>|
| Experimental: Cohort 2<br> | Drug: K0706<br>* Study<br>|
| Experimental: Cohort 3<br> | Drug: K0706<br>* Study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| minimum concentration of study drug cerebrospinal fluid (CSF) |  | Day 8 |
Cervical Recuperation After Vaginal Delivery

Study Overview
=================
Brief Summary
-----------------
Patients after vaginal delivery will undergo 3 trans-vaginal ultrasounds in order to examine the process of cervical recuperation post delivery.

Detailed Description
-----------------
Patients after vaginal delivery will be recruited after receiving a full explanation and signing an informed consent. The goal of the study is to examine cervical length after vaginal delivery at 3 different time intervals: 8 hours post delivery. 24 hours post delivery. 48 hours post delivery. At each interval a trans-vaginal ultrasound will be performed, evaluating cervical length. At the end of the 3rd and final ultrasound, the patient will finish her participation in the study/ Information regarding obstetric conditions such as labor induction, gestational age at the time of delivery etc. will be collected from patients' electronic files.

Official Title
-----------------
Sonography Evaluation of Cervical Recuperation After Vaginal Delivery

Conditions
-----------------
Cervix

Intervention / Treatment
-----------------
* Device: Trans-vaginal ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient after vaginal delivery. Exclusion Criteria: Any patient after cesarean section.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients after vaginal delivery<br>Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery. | Device: Trans-vaginal ultrasound<br>* Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical length after vaginal delivery. | Measurement of cervical length 8, 24, 48 hours after vaginal delivery by trans-vaginal ultrasound. | Up to 48 hours post delivery. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in cervical length after vaginal delivery. | Differences in cervical length after vaginal delivery as a factor of gestational age at delivery, means of labor induction, parity, etc. | Up to 48 hours post delivery. |
Isokinetic Fatigue Index in a Population of Triathletes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the relevance of carrying out a measure of muscular fatigability by isokinetism, in the search for factors favouring micro-traumatic lesions of the lower limbs in a population of triathletes. This is a prospective monocentric pilot study of the before/after type in which the patient is his or her own control, in high-level triathletes practising an endurance sport, who have had more than 7 consecutive days off running due to a musculoskeletal injury during the previous sporting year.

Official Title
-----------------
Pilot Study to Evaluate an Isokinetic Fatigue Index for Prevention Purposes in a Population of Triathletes

Conditions
-----------------
Musculoskeletal Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: isokinetism test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having had a practical running break of more than 7 consecutive days due to a musculoskeletal injury of a lower limb during the previous sport year Willing to comply with all study procedures Having given written consent Socially insured Exclusion Criteria: Pain that does not allow an isokinetic test to be performed Knee joint amplitude less than 100° of flexion or flessum greater than 5°. History of rupture or ligamentoplasty of the anterior cruciate ligament less than 2 years ago History of knee surgery less than 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: isokinetism test in high level triathletes practicing an endurance sport<br> | Diagnostic Test: isokinetism test<br>* measure of muscular fatigability by isokinetism<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fatigue index between the injured leg and the healthy leg | To compare the fatigue index between the injured leg and the healthy leg in high level triathletes injured in the previous season. | the day of inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference of the fatigue index to the difference of the Croisier ratio between the injured leg and the healthy leg | Correlate the difference in the fatigue index to the difference in the Croisier ratio between the injured leg and the healthy leg. | the day of inclusion |